Navigation Links
ChromaDex to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:9/6/2011

IRVINE, Calif., Sept. 6, 2011 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC) announced today that its Chief Executive Officer, Frank L. Jaksch, Jr., will be presenting the company's business strategy and growth opportunities at the 2011 Rodman & Renshaw Annual Global Investment Conference. The event will be held September 11-13, 2011 at the Waldorf Astoria in New York City.

ChromaDex is scheduled to make its presentation on Tuesday, September 13th at 11:30 a.m. local time. The company's presentation is currently available on its website, www.chromadex.com. For further details about the conference, please visit http://www.rodmanandrenshaw.com/conferences?id=162.

For more information about ChromaDex Corporation, visit www.chromadex.com and www.pteropure.com.

About ChromaDex®

ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.  

ChromaDex Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

ChromaDex Contact
Laura Carney
Administrative Assistant
949-419-0288
laurac@chromadex.com

ChromaDex Media Inquiries:
Chandler Chicco Agency
Kerry Sinclair, Media Specialist
310-309-1031
ksinclair@ccapr.com


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Announces Second Quarter 2008 Financial Results
2. ChromaDex Announces 2008 Year End Financial Results
3. ChromaDex Launches pTeroPure Pterostilbene
4. ChromaDex Commences a Clinical Trial on pTeroPureā„¢ Pterostilbene
5. ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President
6. ChromaDex Appoints Curtis Lockshin, Ph.D., to its Board of Directors
7. InterMune to Present at Canaccord Adams Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
9. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
10. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
11. Bionovo to Present at Canaccord Adams Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... 2016 , ... Shimadzu Scientific Instruments will showcase several new ... poster sessions, and present on the analysis of mycotoxins and medical cannabis at ... 10 at the Georgia World Congress Center in Atlanta, Georgia. , Attendees ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... VANCOUVER, British Columbia and MENLO PARK, ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies, today announced that it will present at the ... on Monday, February 8, 2016 at 10:00 a.m. EST in ... Jeffrey Bacha , DelMar,s president and CEO, will provide an ...
(Date:2/4/2016)... 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... to be held February 8-9, 2016, at the Waldorf ... Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ContraVir, ...
Breaking Biology Technology:
(Date:1/8/2016)... and MANCHESTER, United Kingdom , Jan. ... developer of innovative sensor-based diagnostic products, today announced the closing ... new and existing investors.  Proceeds from the financing will be ... , a hand-held device for detecting early-stage pressure ulcers. ... Ireland after receiving CE Mark approval. The device,s ...
(Date:1/7/2016)... NEW YORK , Jan. 7, 2016 ... as regional markets for biometric technologies and devices, identifying ... application market for various types of biometric devices. Includes ... report to: Identify newer markets and explore the ... of biometric devices. Examine each type of biometric technology, ...
(Date:1/7/2016)... , Jan. 7, 2016  A United States ... the first court in the country to interpret a ... lawsuit to go forward against the photo website Shutterfly ... BRIAN NORBERG vs. SHUTTERFLY, INC.; and ... plaintiff alleges that Shutterfly violates the Illinois Biometric Privacy ...
Breaking Biology News(10 mins):